China's Henlius flaunts PD1 asset, challenging big pharma

By Wang Fangqing

With the recent launch of the Avastin (bevacizumab) biosimilar in China, Henlius, the biotech arm of Fosun Pharma (HK: 02196), now has four biosimilars under its belt. However, the Shanghai-based firm is eager to shake off the image of a biosimilars supplier.

“Henlius is a biotech focusing on affordable innovation to meet unmet medical needs. We started from biosimilar, but now we are getting into the innovation stage,” Henlius chief executive Zhang Wenjie said at a press meeting held in Shanghai.